about
Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancersBreast cancer in the personal genomics eraProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerFragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancerOncogenes induce the cancer-associated fibroblast phenotype: metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discoveryMammary gland stem cells and their application in breast cancerA phenotypic mouse model of basaloid breast tumorsBreast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast CancerMolecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73.Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinomaalphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-cateninClinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriersBRCA1 and BRCA2 mutations and treatment strategies for breast cancer.Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastasesGenomic instability in breast cancer: pathogenesis and clinical implicationsInterplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.Breast cancer genomes--form and functionMost basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.A Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate CancersRecurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations.BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.Minireview: Basal-like breast cancer: from molecular profiles to targeted therapiesEmerging Concepts in Breast Cancer Risk Prediction.Metformin and erlotinib synergize to inhibit basal breast cancer.Triple negative breast cancers have a reduced expression of DNA repair genesMYC and Breast Cancer.P16 and p53 play distinct roles in different subtypes of breast cancerSynthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
P2860
Q21260381-5287BF00-254D-49B4-8FDA-332B331B024DQ24602679-BF867BC7-7D20-46EE-9AA3-2F908E9C75BEQ24632628-DA4E57A1-9434-4655-93E8-D18E8BBF6689Q24654216-17C339F6-93A0-4BC1-A3E4-711783194CF6Q26851813-91F3C260-2622-408B-AECB-06932C41A3A2Q28075791-980B86F2-1C90-461B-9EB5-F5B1D074818CQ28480588-A5161B6C-B679-4F8D-94E4-A685C60528F7Q30245184-8BB1D875-1FEA-439E-A6F0-29BB30F45C02Q30496322-73E13A07-E85E-4B87-A1B6-8B9EF61CB4AEQ30497664-B1CC05A3-F90A-4003-AC98-2C721E30F164Q33429434-F449C8DC-03CF-4340-9AE8-4E761B8A86D1Q33479152-25427646-2247-4F16-959B-4AC2D3798490Q33539418-6B016702-E669-4FC2-B98F-6D4BF948AFD1Q33649918-E0F66795-03F8-4F92-8E45-0C8234FC67D9Q33722847-51471FB4-10F7-4B04-A630-C45A64A279DBQ33769821-C924F1CD-A423-4E36-B181-DA4C36888B9EQ33806378-39EAF0DB-EB9A-4C0E-BBDB-9B0E4E38DE2CQ33830446-D4DE7850-AFAB-41B9-BFC4-814150B40B41Q33839776-252E30B1-3E95-4C0C-A2EA-C95D9B87B92FQ33863531-231484C3-757F-4277-AECC-2B74CDCEA212Q33894431-84FD560A-33E1-48AB-A282-7CA0196BEDA1Q33988970-C6098580-9F0F-4240-BCC8-D0F596BA5C36Q33998514-7BAC72ED-DF65-47C0-859D-4F4E8372567CQ34081324-078F431C-E106-4769-9170-AB945D53D1CBQ34207688-3A6821BE-E3FE-4651-884E-86E6FC7CD61AQ34248718-3FDAB337-6767-43D6-A9C5-42097494E6E3Q34456552-CE45566F-DE31-41E4-B582-D6DB188C2066Q34477787-D1EFB34F-B945-4E72-9FB8-2560476DC0A4Q34489002-9A25248E-E2DB-4AE8-B480-2D52BF02E426Q34512811-481A0C3E-F8E6-4027-AE13-FE57A5E64DF5Q34539782-96BEAA83-91D2-4415-9385-ABADE8D10DDEQ34550979-677D1A14-15FB-437B-A39F-B98E2BCFBBDFQ34551543-38553B13-2668-4A08-AC44-379EC6A4D29AQ34562257-39B11A6B-BB1F-4E40-AB84-81D41A6240FCQ34670325-0072943F-457D-4DB2-9D32-4A21E62D4BE9Q34786488-7C755429-7F7E-4CC1-902E-75892E89B45CQ34794035-D4FBC189-275B-4E57-9284-E0AFF0366F33Q34972381-F8E7212B-A075-45C5-BA0E-837153D44C40Q35022751-453A34C4-C2BA-45D2-B247-ED4C1737C849Q35051154-0FC51EC6-1D7A-46D8-ADB8-E0BA4937141A
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Basal-like breast cancer and the BRCA1 phenotype.
@ast
Basal-like breast cancer and the BRCA1 phenotype.
@en
type
label
Basal-like breast cancer and the BRCA1 phenotype.
@ast
Basal-like breast cancer and the BRCA1 phenotype.
@en
prefLabel
Basal-like breast cancer and the BRCA1 phenotype.
@ast
Basal-like breast cancer and the BRCA1 phenotype.
@en
P356
P1433
P1476
Basal-like breast cancer and the BRCA1 phenotype.
@en
P2093
Reis-Filho JS
P2888
P304
P356
10.1038/SJ.ONC.1209876
P407
P577
2006-09-01T00:00:00Z